MAPK7 and neoplasm: Therefore, the introduction of ERK5-targeting agents in clinical evaluation should be envisioned as part of combination regimens designed to avoid resistance and tumor recurrence, bringing together conventional cytotoxic drugs and innovative targeted therapies.